Navigation Links
Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
Date:1/8/2008

BOSTON, Jan. 8 /PRNewswire/ -- Surface Logix today announced positive results in the Company's Phase 2a clinical trial of SLx-2101 in hypertension. The randomized, double-blind, placebo-controlled crossover Phase 2a study in 60 patients with uncontrolled hypertension demonstrated that SLx-2101 caused clinically significant reductions in blood pressure and was well tolerated. The trial was designed to examine the safety, tolerability and effect on blood pressure in patients of repeat oral doses of SLx-2101 once daily for up to 14 days.

"These data confirm the promise of efficacy seen in earlier clinical trials, and we plan to initiate a Phase 2b study of SLx-2101 in hypertension in the third quarter of 2008," said Jim Mahoney, President and CEO of Surface Logix. "We believe that with our demonstrated 24-hour coverage from once daily dosing and excellent tolerability profile, we will be able to uniquely position SLx-2101 in several segments of the hypertension market."

SLx-2101 is an oral, potent, selective, fast-onset, long-acting PDE5 inhibitor. Other PDE5 inhibitors have traditionally been used to treat erectile dysfunction (ED). SLx-2101 was designed specifically to expand the therapeutic potential of PDE5 inhibition beyond ED into larger cardiovascular markets such as hypertension. SLx-2101 is uniquely positioned among the known PDE5 inhibitors to address cardiovascular disease because, compared to currently marketed PDE5 drugs, SLx-2101 preferentially distributes into cardiovascular tissue. With its large volume of distribution, SLx-2101 achieves sustained plasma levels and a long duration of action, without showing accumulation upon repeat dosing. This allows for daily or on demand dosing with a predictable response in a number of cardiovascular disorders that currently marketed PDE5 therapies cannot adequately address.

"To achieve efficacy in cardiovascular disease, your compound has to get into the right tissues," commented Dr. Pau
'/>"/>

SOURCE Surface Logix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Surface Logix, Inc. to Present at the Piper Jaffray Health Care Conference
2. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
3. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
4. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
5. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Osteoarthritis
6. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
7. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
8. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
9. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
10. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
11. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... Dec. 4 Thermographic Diagnostic I...er in Marlton, New Jersey continues to provide sup...omuscular system, thyroid, dental, TMJ and sinus r...s associated with these areas. ,, Thermography... entire infrared range of the electromagnetic spec...
(Date:12/4/2009)...c. 4 Oxygen Biotherapeut...ed that the first patient has been enrolled in the...rial in Switzerland for use of Oxycyte(TM) emulsio...Company,s perfluorocarbon (PFC) therapeutic oxygen...tance in improving the outcome of patients with se...
(Date:12/4/2009)...LAKE FOREST, Ill., Dec. 4 /PRNewswire-FirstCall/ -...pecialty pharmaceutical and medication delivery co...ration 50 mL and 100 mL VisIV(TM) containers for i...ow offers a complete size range (50 mL to 1 L) of ...IV product. The launch of the 50 mL and 100 mL con...
Breaking Medicine Technology:Discover Health Through Awareness 2Discover Health Through Awareness 3Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4Champions Biotechnology Partners with Do Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft 28TM 29 Testing 13061 1Champions Biotechnology Partners with Do Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft 28TM 29 Testing 13061 2Champions Biotechnology Partners with Do Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft 28TM 29 Testing 13061 3Champions Biotechnology Partners with Do Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft 28TM 29 Testing 13061 4U S News Media Group Announces 2009 10 Americas Best Hospitals 51886 1U S News Media Group Announces 2009 10 Americas Best Hospitals 51886 2U S News Media Group Announces 2009 10 Americas Best Hospitals 51886 3U S News Media Group Announces 2009 10 Americas Best Hospitals 51886 4Cancer Patients Benefit From Speed Accuracy of RapidArc Radiotherapy Treatments 51882 1Cancer Patients Benefit From Speed Accuracy of RapidArc Radiotherapy Treatments 51882 2Cancer Patients Benefit From Speed Accuracy of RapidArc Radiotherapy Treatments 51882 3
...G, Md. and CARLSBAD, Calif., April 18, 2007,/PRNew...Inc. today,announced data from a preclinical study...onal antigen (CEA) were shown to prevent,subcutane... An,established marker for tumor progression, CEA ... human carcinomas. These data,presented yesterday...
... Tumor Origin May Be Useful in Cancer Treatment,De...ad Genetics, Inc.,(NASDAQ: MYGN) (<a target="_blan... announced today that,it presented studies for a n...original location of a metastatic tumor, on Monday...ican Association,for Cancer Research (AACR) in Los...
Other Medicine Technology:Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 2Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 3Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 4Micromet and MedImmune Present Data From Preclinical Study of New,BiTE Molecule Targeting CEA 5Myriad Genetics Presents Tumor Origin Technology at AACR 2Myriad Genetics Presents Tumor Origin Technology at AACR 3
(Date:12/4/2009)...ric cancers, particularly Ewing sarcomas and tumor...w study published online December 4 in the Journa...y was undertaken because there is limited research...ars) for pediatric cancer patients. , Karen Wasi...d Blood Disorders Service, Children,s Healthcare o...
(Date:12/4/2009)...Hopkins publishing in the December issue of Neopl...led "Twist" may be the proverbial red flag that ca...ressive, metastatic breast cancer from other breas...ting that it is a relatively rare subgroup of stem... scientists have surmised that this subgroup of ce...
(Date:12/4/2009)...uited annually to participate in clinical trials a...tion (AHRP), and most will be compensated for thei...w payments to volunteers as compensation for time ...sks related to participating in the experiments. ,...different view of clinical trial compensation. Hig...
(Date:12/4/2009)... a phenomenon that was started by people that were...ental work in the US, Canada, and other countries....ple have found that Mexican Dental Vacation is a g... (PRWEB) December 4, 2009 -- ...ican Dental Vacation is seeing their best year eve...
(Date:12/4/2009)...mption leads to success, study finds , ,...ercise, reduced soda consumption and self-weighing...egies for adolescents, a new study shows. , Res...ht-control strategies and lifestyle habits. Sixty-... The responses were grouped into four categories: ...
Breaking Medicine News(10 mins):Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Teens Lose More Weight Using Healthy Strategies 2
...aware of it - they might not be aware of it, but t...g you down. , New research by University of Calga...h says that regardless of their intentions, having...a complex assembly line, said Welsh If you are doi...
...N.C. The standard test for measuring blood sugar ... those on kidney hemodialysis, according to new re...enter. , Wake Forest investigators reported in K...patients and physicians. Hemodialysis, in which bl...
...s available in French . , Montreal, February 20...fight against age-related macular degeneration, or... of people. An international team, led by research...y edition of the medical journal PLoS Medicine, th...
... deficiencies in early pregnancy can cause locomot...earch from the Swedish medical university Karolins... brain development and could affect routine pregna...untreated. However, scientists are unsure about wh...
...0 LCA-Vision Inc. (Nasdaq:,LCAV), a leading provi...LasikPlus brand, announced today that its Board of...ount of $0.18 per share. The dividend will be,paya...r vision correction services,under the LasikPlus b...
...., Feb. 20 When Avaya rolls its,18-wheel Mobile B...IMSS08,next week, onboard will be a broad range of...ping healthcare organizations address critical,com...d services., As healthcare organizations increasi...
Other Medicine News:Health News:Who's slowing you down? 2Health News:Standard test for blood sugar control not accurate in diabetic dialysis patients 2Health News:AMD discovery: New hope for treatment of vision loss 2Health News:Avaya Unified Communications Solutions Help Healthcare Organizations Address Multi-Site, Mobile Workforce Challenges 2Health News:Avaya Unified Communications Solutions Help Healthcare Organizations Address Multi-Site, Mobile Workforce Challenges 3Health News:Avaya Unified Communications Solutions Help Healthcare Organizations Address Multi-Site, Mobile Workforce Challenges 4
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
Medicine Products: